Texas A&M Football

Lunch with Liucci: Billy Liucci joins TexAgs Live (Monday, December 9)

TexAgs co-owner and executive editor Billy Liucci joined TexAgs Live on Monday morning as Texas A&M accepted its invitation to the SRS Distribution Las Vegas Bowl. Liucci discussed Buzz Williams' 8-2 record, the lastest NFL Draft and transfer portal news and much more.
By Billy Liucci
December 9, 2024
7.1k Views
Discuss
Story Poster
Photo by Katie Smith, TexAgs

TexAgs co-owner and executive editor Billy Liucci joined TexAgs Live on Monday morning as Texas A&M accepted its invitation to the SRS Distribution Las Vegas Bowl. Liucci discussed Buzz Williams' 8-2 record, the lastest NFL Draft and transfer portal news and much more.


Segment 1 (00:00:00 - 02:59:18)

  • For basketball, we are not even to conference play yet, and you have wins over Texas Tech and Creighton, who beat No. 1 Kansas and the fact that they are Creighton...
To view this content, you must be a TexAgs Premium subscriber.
Try Premium for $1
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial
Discuss
Tags
Buzz Williams Mike Elko TexAgs Live David Nuño Will Muschamp 12th Man Foundation Kirby Smart TexAgs Live Feature Jimbo Fisher Lunch with Liucci Transfer Portal Dan Lanning
Show All
Glenn Schumann Jacob Zeno Texas A&M vs. Purdue Texas A&M vs. Texas Tech Texas A&M vs. USC Kam Dewberry Shemar Stewart Le'Veon Moss Marcel Reed Football Basketball Texas A&M Arkansas Kansas Texas Tech Texas Rutgers Auburn Purdue USC Wake Forest Ohio State Creighton UAB Oregon 2024
SPONSORED BY
12th Man Foundation
More Football
See All →
Texas A&M remains at No. 19 in Associated Press poll entering Week 2
By Richard Zane
Press Conference: Ratcliffe, Concepcion speak as A&M preps for Utah State
By TexAgs
TexAgs Rewind (9/2)
By TexAgs Live
Former players McCoy & Pugh offer insight on A&M's win over UTSA
By David Nuño
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.